The search for a safer and more tolerable anticoagulant alternative to warfarin has been the
holy grail of thromboembolic research for decades. With its capacity to reduce the risk of …

Background and Purpose—More than 2 million Americans have atrial fibrillation, and
without antithrombotic therapy, their stroke rate is increased 5-fold. In randomized controlled …

The aim of this study was to determine the economic impact of warfarin prophylaxis in
nonvalvular atrial fibrillation compared to no prophylaxis in light of the established clinical …

Objective To estimate the quality‐adjusted life‐years (QALY s), costs, and cost‐effectiveness
of high‐dose edoxaban compared with adjusted‐dose warfarin in patients at risk for stroke …

Objective: Results of randomized clinical trials (RCT) demonstrate that novel oral
anticoagulants (NOAC) are effective therapies for reducing the risk of stroke in non-valvular …

Objective This study aimed to estimate the cost effectiveness of non-vitamin K oral
anticoagulants (NOACs) compared with warfarin for stroke prevention in patients with non …

Recently, novel oral anticoagulants (NOACs) have been approved for stroke prevention in
patients with atrial fibrillation (AF). Although these agents overcome some disadvantages of …

Misalignment between evidence-informed clinical care guideline recommendations and
reimbursement policy has created care gaps that lead to suboptimal outcomes for patients …

Background—New anticoagulants may improve health outcomes in patients with atrial
fibrillation, but it is unclear whether their use is cost-effective. Methods and Results—A …

Objective To assess temporal clinical and budget impacts of changes in atrial fibrillation (AF)-
related prescribing in England. Methods Data on AF prevalence, AF-related stroke incidence …